HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Y-mAbs Therapeutics (NASDAQ:YMAB) and maintained an $11 price target for the company's stock.
November 15, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms Buy rating and $11 price target for Y-mAbs Therapeutics, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of the price target by a reputable analyst can instill confidence in investors and potentially lead to a positive short term impact on the stock price. The specific mention of the company and the reaffirmation of the price target suggest a strong belief in the company's value and prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100